INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is the third prevalent cancer and the fourth most common cause of cancer-related mortality worldwide \[[@R1]\]. In China, about 376.3 thousands people were diagnosed as CRC and about 191.0 thousands patients were died of CRC annually \[[@R2]\]. With the development of technology of diagnosis and treatment, many patients could be treated at the early stage of the disease, but the mortality of CRC was still increasing. Numerous studies have shown that high level of circulating vitamin D was associated with decreased CRC risk \[[@R3]--[@R7]\], suggesting a protective role of vitamin D against CRC. Although vitamin D can obtain from diet and even dietary supplements, most vitamin D is photochemically synthesized in the skin exposed to sunlight \[[@R8]\]. Unfortunately, due to changing of lifestyle and environment, reduced outdoor activity and the absence of adequate sun exposure, vitamin D deficiency becomes a common phenomenon both in healthy individuals and in CRC populations \[[@R9]\].

Vitamin D, a kind of trace elements, exists with two major kinds of formations, 25-hydroxy vitamin D (25(OH)D,) and 1,25-dihydroxy vitamin D~3~ (1,25(OH)~2~D~3~). Particularly, 25(OH)D, is the major circulating form of vitamin D\[[@R10]\], thus, the total serum 25(OH)D level is considered to be the best indicator of vitamin D \[[@R11]\]. Transported from liver to circulation, 25(OH)D is bound primarily to vitamin D binding protein (VDBP) and albumin, and a very small fraction remains free or unbound \[[@R12]\]. The latter is called as free 25(OH)D. Besides, albumin shows a weaker affinity to 25(OH)D than that of VDBP, thus, 25(OH)D can easily dissociate from the albumin \[[@R13]\]. Therefore, both free and albumin bound 25(OH)D can bind to vitamin D receptor (VDR) easily in the surface of target tissues and exert biological effects. As a result, free and albumin bound 25(OH)D are regarded as the bioavailable 25(OH)D. On the other hand, VDR is expressed both in normal cells and in malignant dividing cells\[[@R14]\], and is related to cell proliferation, differentiation, invasion and angiogenesis \[[@R15]\]. Moreover, VDBP is a multifunctional protein that belongs to the albumin gene family and is the precursor to the immune-modulatory protein\[[@R16]\], Gc protein-derived macrophage activating factor (Gc-MAF), which is a Macrophage Activating Factor (MAF) that can activate macrophage against cancer cell \[[@R17]\]. Hence, we speculated that the concentrations of peripheral blood vitamin D and VDBP were associated with the survival in patients with CRC.

Recently, several studies reported that 25(OH)D was associated with the risk of CRC \[[@R18]--[@R20]\], and VDBP was not associated with the risk of various cancers, including CRC \[[@R21]\]. However, VDBP was found significantly associated with the concentration of plasma vitamin D \[[@R22], [@R23]\]. Recently, Ying et al. demonstrated that there was no direct association between VDBP and the risk of CRC. And they also found low level of 25(OH)D was associated with the risk of CRC only when circulating VDBP was below the median level \[[@R24]\]. These results indicated that it might be better to combine 25(OH)D and VDBP together for describing the relationship between vitamin D and CRC. Furthermore, two studies have shown an association between low level of total 25(OH)D and poor CRC survival outcome \[[@R3], [@R8]\]. Unfortunately, all of these studies didn\'t further explore the prognostic value of free, bioavailable 25(OH)D and VDBP in CRC patients. Hence, in this study, we aimed to comprehensively assess the prognostic value of VDBP, total, free and bioavailable 25(OH)D in stage I-III CRC patients.

RESULTS {#s2}
=======

The optimal cut-off values of plasma VDBP, total, free and bioavailable 25(OH)D {#s2_1}
-------------------------------------------------------------------------------

The patients were categorized into three tertiles based on the VDBP, total, free and bioavailable 25(OH)D determined by X-title program (Figure [1](#F1){ref-type="fig"}). The VDBP tertiles obtained from our data include the low VDBP tertile group (VDBP\<159.2 ug/ml), middle VDBP tertile (VDBP = 159.2--310.1 ug/ml), the high VDBP tertile (VDBP \> 310.1ug/ml). Likewise, total, free and bioavailable 25(OH)D tertiles also included low, middle and high tertile groups, which were listed in Table [1](#T1){ref-type="table"}.

![X-tile analyses for 5-year overall survival\
The sample of CRC patients was equally divided into training and validation sets. X-tile plots of training sets were shown in the left panels, with plots of matched validation sets shown in the smaller inset. The optimal cut-off values highlighted by the black circles in left rectangular panels were also shown in histograms of the entire cohort (middle panels), and Kaplan--Meier plots were displayed in right panels. *p* values were determined by using the cut-off values defined in training sets and applying them to validation sets. The optimal cut-off values of Free 25(OH)D and Bioavailable 25(OH)D for OS were 0.01--0.01 pg/ml, and 0.58--1.03 ng/ml, respectively. (**A**) Free 25(OH)D. (**B**) Bioavailable 25(OH)D. CRC, colorectal cancer; VDBP, vitamin D binding protein; OS, overall survival.](oncotarget-08-40214-g001){#F1}

###### The cut-off values of plasma VDBP, total, free and bioavailable 25(OH)D

  Group                          Low group   Middle group   High group
  ------------------------------ ----------- -------------- ------------
  VDBP (ug/ml)                   \< 159.2    159.2--310.1   \> 310.1
  Total 25(OH)D (ng/ml)          \< 6.2      6.2--29.9      \> 29.9
  Free 25(OH)D (pg/ml)           \< 0.01     0.01--0.02     \> 0.02
  Bioavailable 25(OH)D (ng/ml)   \< 0.58     0.58--1.03     \> 1.03

Abbreviations: 25(OH)D: 25-hydroxyvitamin D; VDBP: vitamin D binding protein.

Baseline characteristics of enrolled participants {#s2_2}
-------------------------------------------------

The baseline characteristics of CRC patients were summarized in Table [2](#T2){ref-type="table"}. A total of 206 CRC patients with 131 males and 75 females were enrolled in this study. They had a median age of 63 years (range from 30 to 85). Of them, no smoking, no drinking, no diabetes and no hypertension were all in the majority. Colon was the most common location site of the tumor (*n* = 112). A total of 125(60.7%) patients were in stage III, and according to local histopathology grading, 155(75.2%) patients were found in moderate cell differentiation. All patients underwent surgery and 151(73.3%) patients received chemotherapy. During follow-up period, 87 patients (42.2%) died by the date of the recently scheduled follow-up, the median follow-up time was 45 months.

###### The baseline characteristics of patients with colorectal cancer

                                     VDBP       Total 25(OH)D   Free 25(OH)D   Bioavailable 25(OH)D                                                                                                                   
  ---------------------- ----------- ---------- --------------- -------------- ---------------------- ----------- ---------- ---------- ---------- -------- ---------- ---------- ----------- -------- ------ ------- -------
  Total patients         Low         Middle     High            *P*\*          Low                    Middle      High       *P*\*      Low        Middle   High       *P*\*      Low         Middle   High   *P*\*   
  Parameters             *N* = 206   *N* = 40   *N* = 145       *N* = 21       *N* = 59               *N* = 123   *N* = 24   *N* = 19   *N* = 72   115      *N* = 21   *N* = 61   *N* = 124                           
  Age(years)                                                                   0.037                                                    0.116                                     0.555                               0.68
  \> 63                  110         25         79              6                                     38          59         13                    9        42         59                     13       31     66      
  \< 63                  96          15         66              15                                    21          64         11                    10       30         56                     8        30     58      
  Gender                                                                       0.57                                                     0.07                                      0.061                               0.023
  Male                   131         28         91              12                                    44          75         12                    14       52         65                     14       47     70      
  Female                 75          12         54              9                                     15          48         12                    5        20         50                     7        14     54      
  Smoking                                                                      0.402                                                    0.055                                     0.247                               0.324
  Yes                    49          8          38              3                                     15          33         1                     4        22         23                     6        18     25      
  No                     157         32         107             18                                    44          90         23                    15       50         92                     15       43     99      
  Drinking                                                                     0.321                                                    0.371                                     0.401                               0.89
  Yes                    24          3          20              1                                     6           17         1                     1        11         12                     2        8      14      
  No                     182         37         125             20                                    53          106        23                    18       61         103                    19       53     110     
  BMI(kg/m^2^)                                                                 0.01                                                     0.183                                     0.215                               0.508
  \< 22.16               103         28         63              12                                    34          55         14                    13       33         57                     12       27     64      
  \> 22.16               103         12         82              9                                     25          68         10                    6        39         58                     9        34     60      
  Hypertension                                                                 0.228                                                    0.946                                     0.215                               0.12
  Yes                    46          5          35              6                                     13          27         6                     3        21         22                     5        19     22      
  No                     160         35         110             15                                    46          96         18                    16       51         93                     16       42     102     
  Diabetes                                                                     0.487                                                    0.156                                     0.056                               0
  Yes                    30          8          20              2                                     13          14         3                     5        14         11                     10       9      11      
  No                     176         32         125             19                                    46          109        21                    14       58         104                    11       52     113     
  TMN stage                                                                    0.643                                                    0.311                                     0.962                               0.821
  I-II                   81          18         56              7                                     24          51         6                     7        29         45                     8        26     47      
  III                    125         22         89              14                                    35          72         18                    12       43         70                     13       35     77      
  Cell differentiation                                          0.937                                                        0.195                                     0.86                                   0.665   
  H                      20          4          16              0                                     8           10         2                     3        9          8                      2        7      11      
  M                      155         30         106             19                                    39          101        15                    13       49         93                     14       44     97      
  L                      31          6          23              2                                     12          12         7                     3        14         14                     5        10     16      
  Location                                                                     0.02                                                     0.206                                     0.008                               0.049
  Colon                  112         16         88              8                                     27          73         12                    5        47         60                     7        39     66      
  Rectal                 94          24         57              13                                    32          50         12                    14       25         55                     14       22     58      
  Chem                                                                         0.205                                                    0.605                                     0.818                               0.06
  Yes                    151         33         105             13                                    42          93         16                    13       52         86                     11       48     92      
  No                     55          7          40              8                                     17          30         8                     6        20         29                     10       13     32      
  Albumin (g/l)                                                                0.003                                                    0.097                                     0.136                               0.025
  \< 35                  69          11         44              14                                    15          42         12                    6        18         45                     12       15     42      
  \> 35                  137         29         101             7                                     44          81         12                    13       54         70                     9        46     82      
  Death                                                                        0.177                                                    0.371                                     0.013                               0.047
  Yes                    87          13         62              12                                    22          52         13                    13       23         51                     14       22     51      
  No                     119         27         83              9                                     37          71         11                    6        49         64                     7        39     73      

Abbreviations: 25(OH)D: 25-hydroxyvitamin D; VDBP: vitamin D binding protein; BMI: body mass index; Chem: Chemotherapy; H: high cell differentiation; M: moderate cell differentiation; L: low cell differentiation.

Note: The bold represent that *P* value was statistically significant.\*Difference between groups was tested by Chi-square test.

The association between baseline characteristics and clinical prognosis {#s2_3}
-----------------------------------------------------------------------

The association between baseline characteristics and overall survival (OS) in CRC patients were listed in Table [3](#T3){ref-type="table"}. In Kaplan--Meier and univariate analysis, our results showed that age (\< 63 years), no smoking, body mass index (BMI) (\< 22.16 kg/m^2^), no hypertension, no diabetes, TNM stage (I--II), high cell differentiation, albumin (\> 35 g/l), middle and high group of free and bioavailable 25(OH)D were significantly associated with better OS(*P*~all~ \< 0.05; Figure [1](#F1){ref-type="fig"} and Table [3](#T3){ref-type="table"}). Clinical baseline characteristics for the prediction of clinical prognosis were further investigated by multivariate analysis with Cox regression model. Smoking (HR = 1.841, 95%CI = 1.149--2.949, *P* = 0.011), BMI (\> 22.16 kg/m^2^) (HR = 2.004, 95%CI = 1.244--3.228, *P* = 0.004), low cell differentiation (HR = 3.912, 95%CI = 1.130--13.551, *P* = 0.031), albumin (\> 35 g/l) (HR = 0.590, 95%CI = 0.383--0.909, *P* = 0.017) were still associated with clinical prognosis. More importantly, comparing patients in the high group and middle group versus the low group of free 25(OH)D, the adjusted hazard ratio (HR) was 0.442(95%CI = 0.238--0.819, *P* = 0.010) and 0.241(95%CI = 0.117--0.495, *P* \< 0.001) for OS, respectively. Our results indicated that middle and high group of free 25(OH)D, no smoking, BMI (\< 22.16 kg/m^2^), high cell differentiation, albumin (\> 35 g/l) could be considered to be independent markers for better OS of CRC patients.

###### COX regresion based on overall survival

  Parameters                 Total patients   5-year OS   Log-rank *P* value   univariate analysis       multivariate analysis                             
  -------------------------- ---------------- ----------- -------------------- ------------------------- ----------------------- ------------------------- -----------
  **Age(years)**                                          **0.047**                                                                                        
  \< 63                      96               49                               Reference                                         Reference                 
  \> 63                      110              38                               **1.528(1.000,2.334)**    **0.05**                1.237(0.766,1.999)        0.385
  **Gender**                                              0.921                                                                                            
  Male                       131              56                               Reference                                                                   
  Female                     75               31                               0.978(0.631,1.517)        0.922                                             
  **Smoking**                                             **0.03**                                                                                         
  No                         157              59                               Reference                                         Reference                 
  Yes                        49               28                               **1.631(1.040,2.558)**    **0.033**               **1.841(1.149,2.949)**    **0.011**
  **Drinking**                                            0.555                                                                                            
  No                         182              75                               Reference                                                                   
  Yes                        24               12                               1.199(0.652,2.206)        0.559                                             
  **BMI(kg/m^2^)**                                        **0.008**                                                                                        
  \< 22.16                   103              34                               Reference                                         Reference                 
  \> 22.16                   103              53                               **1.778(1.155,2.736)**    **0.009**               **2.004(1.244,3.228)**    **0.004**
  **Hypertension**                                        **0.011**                                                                                        
  No                         160              60                               Reference                                         Reference                 
  Yes                        46               27                               **1.787(1.134,2.816)**    **0.012**               1.544(0.959,2.486)        0.074
  **Diabetes**                                            **0.005**                                                                                        
  No                         176              68                               Reference                                         Reference                 
  Yes                        30               19                               **2.035(1.222,3.388)**    **0.006**               1.403(0.763,2.581)        0.276
  **TMN stage**                                           **0.038**                                                                                        
  I-II                       81               26                               Reference                                         Reference                 
  III                        125              61                               **1.613(1.018,2.556)**    **0.042**               1.147(0.900,1.463)        0.267
  **Cell differentiation**                                **0.03**                                                                                         
  H                          20               3                                Reference                                         Reference                 
  M                          155              67                               **3.584(1.127,11.397)**   **0.031**               2.281(0.699,7.442)        0.172
  L                          31               17                               **4.662(1.365,15.914)**   **0.014**               **3.912(1.130,13.551)**   **0.031**
  **Location**                                            0.569                                                                                            
  Rectal                     94               41                               Reference                                                                   
  Colon                      112              46                               0.886(0.581,1.350)        0.572                                             
  Chem                                                    0.365                                                                                            
  No                         55               20                               Reference                                                                   
  Yes                        151              67                               1.257(0.763,2.073)        0.37                                              
  **Albumin (g/l)**                                       **0.001**                                                                                        
  \< 35                      69               40                               Reference                                         Reference                 
  \> 35                      137              47                               **0.490(0.321,0.747)**    **0.001**               **0.590(0.383,0.909)**    **0.017**
  **VDBP**                                                0.203                                                                                            
  Low                        40               13                               Reference                                                                   
  Middle                     145              62                               1.463(0.805,2.661)        0.212                                             
  High                       21               12                               2.013(0.918,4.416)        0.081                                             
  **Total 25(OH)D**                                       0.23                                                                                             
  Low                        59               22                               Reference                                                                   
  Middle                     123              52                               1.180(0.717,1.943)        0.516                                             
  High                       24               13                               1.794(0.903,3.563)        0.095                                             
  **Free 25(OH)D**                                        **0.008**                                                                                        
  Low                        19               13                               Reference                                         Reference                 
  Middle                     72               23                               **0.353(0.178,0.699)**    **0.003**               **0.241(0.117,0.495)**    **0**
  High                       115              51                               **0.535(0.290,0.985)**    **0.045**               **0.442(0.238,0.819)**    **0.01**
  **Bioavailable 25(OH)D**                                **0.019**                                                                                        
  Low                        21               14                               Reference                                         Reference                 
  Middle                     61               22                               **0.410(0.210,0.803)**    **0.009**               0.807(0.327,1.992)        0.642
  High                       124              51                               **0.485(0.268,0.877)**    **0.017**               0.398(0.082,1.928)        0.253

Abbreviations: OS: overall survival; HR: hazard ratio; 95%CI: 95% confidential interval; Chem: Chemotherapy; 25(OH)D: 25-hydroxyvitamin D; VDBP: vitamin D binding protein; ALB: albumin;BMI: body mass index; L: Low group; M: Middle group; H: High group.

Note: The bold represent that *P* value was statistically significant.

DISCUSSION {#s3}
==========

In this study, we found that low levels of free and bioavailable 25(OH)D were both associated with poor OS, and free 25(OH)D was an independent prognostic factor for OS. To the best of our knowledge, this might be the first research which explored the association of plasma VDBP, total, free and bioavailable 25(OH)D with the prognosis of patients with stage I-III CRC at the same time.

This study indicated that low levels of free and bioavailable 25(OH)D were both associated with poor OS, which indicated that free and bioavailable 25(OH)D had a protective effect from death for CRC patients and had utility as biomarkers for survival monitoring. However, previous studies reported that total 25(OH)D was also associated with the survival of CRC \[[@R3], [@R8]\], which was inconsistent with our study. Maybe this phenomenon could be explained by the number of patients from different tumor stages and different geographic regions. Therefore, further study with larger samples should be applied to confirm this result. Furthermore, different cut-off values determined by different tools could also contribute to this difference. In this study, X-tile program, a robust graphical tool verified by Yale University was used by us to determine the optimum cut-off values. Our study demonstrated that circulating VDBP was not associated with the survival of CRC patients, which was consistent with the recent study by Ying et al. \[[@R24]\]. Theoretically, free and bioavailable 25(OH)D would be more representative for the function of vitamin D than total 25(OH)D because only free 25(OH)D could bind to VDR and play an important role in biological activity \[[@R25]\].

The following mechanisms might explain our results. Almost all CRC patients had abnormal β-catenin signal transduction pathway\[[@R26]\] and 25(OH)D in colon and several other tissues could be converted into hormonally active 1,25(OH)~2~D~3~ which could inhibit the abnormal signal pathway, and promote the differentiation of tumor cells by stimulating β-catenin-TCF-4 target gene \[[@R27], [@R28]\] and inducing E-cadherin \[[@R29], [@R30]\]. Furthermore, the 1,25(OH)~2~D~3~ had direct anti-tumor effect \[[@R31]\] because several oncogenes or anti-oncogenes could be regulated by vitamin D \[[@R32]\], such as TGF-β, TNF-α, p27/Kip1, c-myc, c-fos, c-jun, which were closely associated with the proliferation and differentiation of some specific cells \[[@R33]\]. Some previous studies indicated that TGF-β, which could inhibit the growth of enterocytes, could be antagonized by CRC cells\[[@R34]\], and this resulted in the growth of CRC tissues. However, this process could be interdicted by 1,25(OH)~2~D~3~ through increasing the activity of TGF-β on CRC cells\[[@R35]\]. In addition, 1,25(OH)~2~D~3~ could suppress mitosis by increasing the expression levels of p27/Kip1 and p21/Waf1, inhibiting the activity of cyclin-CDK complex, promoting dephosphorylation of Rb protein, decreasing the transactivation of E2F, and then resulting in the tumor cells stagnated in G0/G1 stage \[[@R36]\].

To our knowledge, it was the first study that synthetically investigated the association between total, free, bioavailable 25(OH)D, VDBP and the prognosis of patients with stage I-III CRC. The previous studies tended to be more concerned about the total 25(OH)D or VDBP with CRC outcome separately. Our study could objectively and comprehensively analysis the association among them and our results were then more accurate than the previous. Besides, all samples were collected between 8:00am and 10:00am in ZhongDa hospital, and the plasma samples were all put in -80 degree centigrade environment before collection for assays, which could minimize the side effects of environmental factors on plasma vitamin D levels.

Undeniably, some limitations were also found in our study. Firstly, only 206 patients were enrolled and the small size couldn\'t represent the whole population which might decrease the power of our results. So further study with more patients included should be conducted. Secondly, the concentrations of 25(OH)D and VDBP were assayed at only one point instead of dynamic monitoring, which might have an important side effect on our results because the plasma 25(OH)D level would increase by extral multivitamin use, physical activity, and exposure to sunshine. Thirdly, only OS was accessed in this study, which was not able to exclude the influence of cancer unrelated to death. The last but not least, there was a lack of an external validation cohort to test whether actively supplementing vitamin D could increase survival time of CRC patients.

In conclusion, our findings suggested that higher levels of free and bioavailable 25(OH)D were associated with better OS in I-III stage CRC patients, and free 25(OH)D was an independent prognostic factor for OS.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

A blanket search was conducted to look for the patients initially diagnosed with CRC from February 2011 to February 2012 in ZhongDa Hospital (Nanjing, Jiangsu, China). All patients were diagnosed through colonoscopy, confirmed with histo-pathological examination and underwent surgery. Patients with any diseases which could have an impact on the metabolism of vitamin D or calcium were excluded from our study, such as serious renal or liver diseases, parathyroid gland diseases, active infection, etc. The present study was approved by the Institution Ethics Commission of ZhongDa Hospital and Southeast University, and informed consents were obtained from all participants.

Information of patients {#s4_2}
-----------------------

We collected the characteristics of all enrolled patients, including sex, age, smoking, drinking, BMI, diabetes, hypertension, treated with surgery or chemotherapy, and the treatment data. In addition, the location of cancer, pathological types, tumor stage were also collected. All information above were obtained from the hospital medical record of ZhongDa Hospital.

Blood sample saving and plasma vitamin D assay {#s4_3}
----------------------------------------------

All samples were collected within seven days before operation from Clinical Laboratory of ZhongDa Hospital. To minimize the effect of ultraviolet or temperature on blood samples, the collecting time was controlled between 8:00am and 10:00am, and the plasma samples were put in -80 degree centigrade environment until assay. The measurement of blood total 25(OH)D was conducted using direct competitive enzyme-linked immunosorbent assay with the 25(OH)D immunoassay kit (HCB Ltd, Vancouver, Canada). The concentration of plasma VDBP was measured using human VDBP immunoassay kit (R&D Systems, Minneapolis, USA). Considering the coefficient of variations of inter- and intra-batch about the two kinds of kit, all plasma samples were distributed to triplicate randomly while measuring. The measurement of plasma albumin concentration was also carried out using a bromocresol green dye assay with Beckman automatic biochemical analyzer (AU680) (Beckman Coulter lnc, Tokyo, Japan). After all above steps, free and bioavailable 25(OH)D were calculated from the concentrations of total 25(OH)D, VDBP and plasma albumin according to the mathematical equations provided by Bhan et al\[[@R37]\]. All assays were conducted in April of 2014. The methods were carried out according with the approved guidelines.

Follow up {#s4_4}
---------

Patients were followed up regularly dating up to December 10, 2016 or until death according to 7th edition of the TNM-UICC/AJCC classification for CRC (every 3--6 months for first 2 years, every 6 months for the third to fifth years). The OS was defined as the time from the date of diagnosis to last follow-up or death. Follow-up data for patients were computed from medical records, physical examinations, laboratory examinations or telephone follow-up. All works were conducted by two investigators and any disagreement was solved by discussion.

Statistical analysis {#s4_5}
--------------------

IBM SPSS Statistical 20.0 (SPSS Inc. Chicago, IL, USA) and X-tile 3.6.1 (Yale University, New Haven, CT, USA) were used for statistical analysis. Differences between high- and low-level group patients were evaluated using the χ2 test or Mann-Whitney U test. For clinical practice, the continuous variables were changed to categorical variables, and the cutoff values of VDBP, total, free and bioavailable 25(OH)D were determined by X-tile 3.6.1 (Yale University, New Haven, CT, USA). OS curves were established according to the Kaplan--Meier method and the differences were analyzed by the log-rank test. To identify the independent factors, multivariate cox regression analyses were performed. Variables with a *P value* less than 0.10 in the univariate cox regression analysis were entered into the multivariate cox regression model using backward conditional method. Two-tailed *P* values less than 0.05 were considered to be statistically significant.
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